We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Sigilon Therapeutics Inc (SGTX) USD0.001

Sell:$1.85 Buy:$2.85 Change: $0.38 (12.26%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.38 (12.26%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.38 (12.26%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Sigilon Therapeutics, Inc. is a biopharmaceutical company with a platform of biomedical technologies and cell therapies created to avoid host detection and foreign body responses with a goal of providing functional cures to patients with chronic diseases. The Company has developed its Shielded Living Therapeutics (SLTx) platform, which combines cell engineering in biocompatible materials and enables its product candidates to produce a range of therapeutic molecules, which may be missing or deficient, such as proteins, including therapeutic proteins and antibodies, and hormones. The Company is designing its product candidates to be off-the-shelf, durable, controllable and redosable, without requiring modification of the patient’s genes or immunosuppression. Its lead product candidate, SIG-001, is designed to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A by continuously secreting human Factor VIII (FVIII).

Contact details

100 Binney Street, Ste 600
United States
+1 (617) 3367540

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$101.45 million
Shares in issue:
32.31 million
United States
US dollar

Key personnel

  • Rogerio Vivaldi Coelho
    President, Chief Executive Officer, Director
  • Glenn Reicin
    Chief Financial Officer, Treasurer
  • May Orfali
    Executive Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.